
Publication
Government of Alberta launches nuclear energy engagement
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
Global | Publication | June 2016
In this, our eleventh issue of Cultivate, we focus on the Australian food and agribusiness sector, an industry which feeds approximately 60 million people worldwide. Our focus includes an interview with Geoff Honey, CEO of Grain Trade Australia about the role of Australia’s grain industry in global and particularly Asian food security. We also explore the impact of COP 21 and the Paris agreement by reviewing Australia’s mitigation efforts towards climate change, and take a look at the likely impact of the Australian Government’s recent Agricultural Competitiveness White Paper. Finally, as the Australian government looks to strengthen the agricultural sector in its region, we review the new foreign investment regime and how it seeks to establish stronger competition in agricultural supply chains.
Beyond Australia we shine a spotlight on a range of topics from the consultation on a proposed “Sugar Tax” in the UK and workplace legislation affecting farmers in Canada to the tensions between the EU’s Common Agricultural Policy and its competition law policy. We also examine the challenges facing French agriculture industry and investigate how opportunities for farmers in the US significantly expand the quinoa production, an increasingly popular food which has traditionally been grown principally in South America.
Publication
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
Publication
Health Canada has proposed a major change to the regulation of biosimilar drugs that may accelerate biologic patent litigation in Canada. Following the lead of other jurisdictions, Health Canada has proposed that biosimilar manufacturers no longer be required to conduct phase 3 clinical trials to enter the Canadian market.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025